Physician profile
Anu Sury
NPI 1194933739
$3,282.89
in general payments reported to CMS, 2019-2025
37 companies · $539 in 2025
The $539 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $113 · 2022: $832 · 2023: $678 · 2024: $803 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $430.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $425.92 | 2022-2025 | Vraylar, Ubrelvy |
| Astellas Pharma US INC | $274.25 | 2022-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $254.37 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Amgen INC. | $210.91 | 2019-2024 | Otezla, Repatha, Prolia |
| Pfizer INC. | $208.91 | 2020-2025 | |
| Glaxosmithkline, LLC. | $175.22 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Supernus Pharmaceuticals, INC. | $135.18 | 2022-2023 | Qelbree |
| Astrazeneca Pharmaceuticals Lp | $131.40 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $109.02 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.18 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $98.35 | 2020-2023 | |
| Amarin Pharma, INC. | $64.69 | 2019-2022 | |
| Dexcom, INC. | $56.94 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $56.54 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Sury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.